HIV
The Pharmacy Times® human immunodeficiency virus (HIV) resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.
What can we help you find?
As patients with HIV are living longer, they are also being diagnosed with chronic conditions that have become increasingly common in recent decades, putting them at higher risk of COVID-19 hospitalization and death.
At the virtual 2020 ASHP Midyear Clinical Meeting and Exhibition, Elyse Tung, PharmD, BCACP, discussed key counseling points for pharmacists to address with patients when prescribing and managing PrEP.
The FDA has approved Rukobia (fostemsavir) for the treatement of human immunodeficiency virus 1 (HIV-1) infection.
Additional non-oral options could provide more manageable forms of PrEP treatment for patients, potentially increasing global uptake of PrEP in the future.
Further, the study showed cabotegravir was 89% more effective than daily oral FTC/TDF for pre-exposure prophylaxis (PrEP).
Further, the study showed cabotegravir was 89% more effective than daily oral FTC/TDF for pre-exposure prophylaxis (PrEP).
The US Department of Health & Human Services released guidance at the beginning of the pandemic clarifying guidelines regarding best practices in HIV care.
This activity is supported by an educational grant from Janssen Therapeutics, division of Janssen Products, LP.
Conduct proper review and evaluation of ARV and DOAC pharmacokinetics and metabolism prior to recommending treatment.
Although HIV self-tests are available for retail purchase by consumers, the CDC encourages health departments to consider self-testing as an additional strategy to reach individuals most affected by the virus.
This activity is supported by an educational grant from Janssen Therapeutics, division of Janssen Products, LP.
Insurance companies are currently investigating the option of modifying which medications they will cover for HIV pre-exposure prophylaxis (PrEP) therapy, with broad implications for patient access.